Back to search results

Study of RMC-6236 for Advanced Solid Tumors with RAS Mutations

This study is testing a new oral medication called RMC-6236 for adults with advanced solid tumors that have specific changes (mutations) in their RAS genes. These tumors include certain types of non-small cell lung cancer, colorectal cancer, pancreatic cancer, and other advanced solid tumors. RMC-6236 works by targeting the active form of RAS proteins. The main goals are to see how safe RMC-6236 is, what side effects it might cause, and to find the best dose. To join, your tumor must have specific KRAS G12 or other RAS mutations, identified through DNA testing. The study plans to enroll up to 754 participants, but its current status is unclear.

Study design
This is a Phase 1/2 study, meaning it's in the early stages of testing. It is an open-label study, so both you and your doctors will know you are receiving RMC-6236. The study aims to enroll up to 754 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The study will track side effects and laboratory results for up to 2.5 years. Dose-limiting toxicities will be assessed within 21 days.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05379985

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Recruiting
PHASE1Ages 18+InterventionalTreatment
Revolution Medicines, Inc.
~754 participants
Updated 2026-05-15 on ClinicalTrials.gov
What's tested:RMC-6236

At a glance

Recruiting sites
21 of 21 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence and severity of treatment-emergent Adverse Events (AEs) and serious AEs, including incidence and severity of findings in laboratory values and vital signs
Measured over up to 2.5 years
+1 more outcome measured

Conditions

Non-small Cell Lung Cancer (NSCLC)
Colorectal Cancer (CRC)
Pancreatic Ductal Adenocarcinoma (PDAC)
Advanced Solid Tumors

Explore related trials

Colorectal CarcinomaLung Non-Small Cell CarcinomaPancreatic Ductal AdenocarcinomaSolid NeoplasmGTPase KRasRAS Family Oncogene

Where it's being run

21 sites across 13 states
Texas4
New York3
California2
Ohio2
Tennessee2
Florida1
Georgia1
Louisiana1

Study leadership

  • Revolution Medicines, Inc. · STUDY_DIRECTOR · Revolution Medicines, Inc.

Who to contact

Revolution Medicines, Inc.
[email protected]
1-844-273-8633
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Histologically confirmed advanced solid tumor with specific KRAS G12 mutations (dose escalation) or RAS mutations (dose optimization/expansion) identified through deoxyribonucleic acid (DNA) sequencing. PDAC with wild-type RAS (expansion).
Treatment naive or have received prior standard therapy appropriate for tumor type and stage
Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Adequate organ function

Exclusion

Primary central nervous system (CNS) tumors
Active, untreated brain metastases
Known or suspected impairment of gastrointestinal function that may prohibit ability to swallow or absorb an oral medication
History of any other unstable or clinically significant concurrent medical condition that would, in the opinion of the investigator, jeopardize the safety of a participant, impact their expected survival through the end of the study participation, and/or impact their ability to comply with the protocol prior/concomitant therapy

What this trial measures

  • Incidence and severity of treatment-emergent Adverse Events (AEs) and serious AEs, including incidence and severity of findings in laboratory values and vital signsup to 2.5 years
  • Number of Participants with Dose-Limiting Toxicity (DLT)21 days